AZD-5153
As of the edition of 20 October 2026, AZD-5153 is a small molecule: went quiet in 2021; acts on BRD4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2021
- Kind
- Small molecule
- Registered trials
- 3, 0 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system; Digestive system; Hormones; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 companies on route A because of this drug.
Companies on route A for this drug
In the product3 companies are on route A because of AZD-5153.
See the 3 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| BRD4 | Bromodomain-containing protein 4 | O60885 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Beat AML | Lead sponsor of trials | 2016 to now |
| AstraZeneca | Lead sponsor of trials | 2017 to now |
| Acerta Pharma | Lead sponsor of trials | 2018 to now |